Peter Keeling of Diaceutics
In the Company of Mavericks
00:00
Diasetics
I think we're on a 30 or 40 year paradigm shift towards the personal treatment for individual patients today. We're still trying to find those genetic subtypes, you know, there could be a quarter of breast cancer patients who will respond to a particular drug. So it's finding those subsets and treating them with these new drugs that sort of where we're at at the minute. And what I've built around diasetics kind of key pillars of helping the pharmaceutical industry do that in a much more simplified way.
Transcript
Play full episode
